Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a pharmaceutical company focused on developing abuse-deterrent opioid and stimulant formulations through its proprietary drug-technology platforms. The company entered public markets via a SPAC transaction, with the blank-check vehicle completing its initial public offering in 2018 within the healthcare and life sciences sector. The May 2020 Form 10-Q filing, accession number 0001213900-20-011276, reflects quarterly regulatory reporting activity during the pre-combination period, a stage when SPAC targets begin establishing their public disclosure record ahead of deal close. Ensysce operates in the specialty pharmaceuticals segment, targeting the significant unmet need for tamper-resistant controlled substances. To access full filing history, deal timelines, sponsor details, and real-time SPAC analytics for Ensysce and thousands of other transactions, sign up for complete data at SpacDesk.